% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • godwinpeak godwinpeak Sep 14, 2013 5:27 PM Flag

    Omontys: The Wonder Drug that Will Make AFFY Longs Rich

    An excerpt from a WSJ article:

    About 25,000 patients have been treated with Omontys, Affymax said Saturday. Of those, around 0.2%—or about 50 patients—have experienced hypersensitivity, a sometimes fatal condition that can arise when the body's immune system reacts to drugs or other foreign intrusions, such as bee stings.

    About five patients were reported to have died after receiving Omontys, according to the figures provided by Affymax, and around 17 had severe allergic reactions requiring immediate medical help and, in some cases, hospitalization. The reactions could occur within 30 minutes of the first dose.

    Health-care providers were told to cease administering Omontys, approved by U.S. regulators in March 2012, and to quarantine supplies until further notice.

    PS. AFFY said the reactions were geographically diverse and not limited to any specific manufacturing lot or lots. AFFY Longs nevertheless keep repeating that the Omontys allergic reactions was most likely due to "human error", and not the medicine itself.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • P.s. You mean humans make errors in only one specific location?

      Of the 5 patients who died, how many died because of the drug? Latest understanding i have is 3 tied to the drug. I could be wrong. How does that compare to the amgen drugs again? I would like to see your twisted explanation once more.

      By the way, have you sold your short position? If you believe it's going to around $2 because of mm manipulation wouldn't it be a good idea to sell out now and buy back when it gets to around that $2?

      Takeda announced not selling in japan long ago, you haven't answered that one as yet. Did they announce they would engage a marketing partner to do that or not? I already know the answer. Any good lawyer would know the answer to a question before he asks it, would you not agree? A good lawyer would also not open the door to information which can damage his/her case.

      You mentioned in that long diatribe words to the effect that takeda did not announce commitment to returning omontys to market. Do you mean takeda is not investigating further? If they are investigating further is that not an announcement in itself?

    • Longs are not repeating that the Omontys allergic reaction was due to human error. Longs are repeating that patients dying from anaphylaxis is human error. Come on Godwinpeak. You know better than that.

0.075-0.0090(-10.71%)May 24 2:49 PMEDT